Dr Agarwal's Hea Q1 FY26 Earnings Call Analysis
Revenue, margin, capex, fundraise and order book outlook from management commentary.
Management growth scorecard
Revenue
N/A
Margin
N/A
Fundraise
N/A
Order
N/A
Capex
N/A
0 of 0 growth signals are positive — mixed outlook.
Full analysisRevenue guidance
See what Dr Agarwal's Hea management said on margin guidance — free account, 30 seconds.
Fundraise plans
See what Dr Agarwal's Hea management said on order book — free account, 30 seconds.
Capex plans
Track Dr Agarwal's Hea — get its next earnings analysis in your feed
How does Dr Agarwal's Hea rank vs peers in Healthcare Services?
Pro featureHow does Dr Agarwal's Hea rank in Healthcare Services?
Compare Dr Agarwal's Hea against every Healthcare Services company (Q1 FY26) on revenue, margins and earnings-call signals.
Continue your research
What Dr Agarwal's Hea's management said in earlier quarters
Others in Healthcare Services this season
- KMC Speciality Hospitals (India) Ltd (Q4 FY26)
Q4 FY’26 Revenue from Operations: INR 82.3 Cr, up 35.0% YoY from INR 60.9 Cr in Q4 FY’25 (Page 20) . Key concall takeaways from KMC Speciality Hospitals…
- KMC Speciality Hospitals (India) Ltd (Q1 FY27)
Q1 FY'27 Revenue from operations: INR 91.8 Cr, up 38% YoY from INR 66.6 Cr in Q1 FY'26. Key concall takeaways from KMC Speciality Hospitals (India) Ltd's Q1…
- Suven Life Sciences Ltd (Q1 FY22)
The provided pages of the Suven Life Sciences investor presentation do not contain any specific revenue, sales, or volume figures for any quarter. Key concall…
- Vimta Labs Ltd (Q3 FY25)
Q3 FY25 Revenue from Operations: ₹899 Mn . Key concall takeaways from Vimta Labs Ltd's Q3 FY25 earnings call — and how it ranks against sector peers.